Lubinus SPII Hip Stem Target Trial Emulation

Condition(s) studied

Investigational drug(s) / intervention(s)

Lubinus SPII hip stem 130mm: Shorter length of the SPII hip stem

Lubinus SPII hip stem 150mm: Longer length of the SPII hip stem

Study summary

The research questions this study aims to answer are as follows:

Primary research question:

"Do primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis with the 150mm Lubinus SPII hip stem have better mortality and stem revision rates than primary total hip arthroplasties with the 130mm hip stem?"

Secondary aims include:

* How does line-to-line cementation, compare to undersized cementation in primary total hip arthroplasty for patients with OA, hip fracture, or osteonecrosis when comparing equal size Lubinus SPII hip stems implanted with different cementation techniques?
* Does the Lubinus SPII 150mm hip stem perform equal to the Lubinus SPII 130mm hip stem in primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis when comparing patient reported outcome measures?

To answer these questions, this study has been allowed use of registered data from the LROI (dutch arthroplasty registry) and the SAR (swedish arthroplasty registry). After exclusion of patients who did not meet inclusion criteria between 2007-2020, approximately 110000 patients remain eligible for analysis.

Eligibility

Primary outcome measure(s)

• Mortality rate — From date of surgery to date of event (death), minimally 2 years up to 16 years (2007-2023)
  Time from primary hip surgery to patient death, per hip stem length
• Revision rate — From date of surgery to date of event (revision), minimally 2 years up to 16 years (2007-2023)
  Time from primary hip surgery to implant failure, per hip stem length

Trial sites (1)

More JointResearch trials in the Netherlands